StockNews.com Downgrades Can-Fite BioPharma (NYSE:CANF) to Sell

Can-Fite BioPharma (NYSE:CANF) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a report released on Wednesday.

Separately, EF Hutton Acquisition Co. I raised shares of Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th.

Can-Fite BioPharma Price Performance

CANF stock opened at $2.21 on Wednesday. The stock has a market capitalization of $7.82 million, a PE ratio of -1.25 and a beta of 1.41. The company’s 50-day moving average is $2.29 and its 200-day moving average is $2.51. Can-Fite BioPharma has a 1 year low of $1.83 and a 1 year high of $4.69.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC boosted its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.